Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Adam Antczak"'
Autor:
Jørgen Vestbo, Wim Janssens, Chaicharn Pothirat, Sibel Naycı, Adam Antczak, Dinesh Saralaya, Uffe Bodtger, Nicolas Roche, Gaëtan DESLEE, Stephen Field, Miodrag Vukcevic, Nicolino Ambrosino
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2016, 374 (23), pp.2222-2234. ⟨10.1056/NEJMoa1516385⟩
New England Journal of Medicine, 2016, 374 (23), pp.2222-2234. ⟨10.1056/NEJMoa1516385⟩
FLAME Investigators & Bødtger, U 2016, ' Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD ', The New England Journal of Medicine, vol. 374, no. 23, pp. 2222-2234 . https://doi.org/10.1056/NEJMoa1516385
New England Journal of Medicine, Massachusetts Medical Society, 2016, 374 (23), pp.2222-2234. ⟨10.1056/NEJMoa1516385⟩
New England Journal of Medicine, 2016, 374 (23), pp.2222-2234. ⟨10.1056/NEJMoa1516385⟩
FLAME Investigators & Bødtger, U 2016, ' Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD ', The New England Journal of Medicine, vol. 374, no. 23, pp. 2222-2234 . https://doi.org/10.1056/NEJMoa1516385
BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe4acaa29c8e8cb8f5ca38a6085fe52
https://lirias.kuleuven.be/handle/123456789/545522
https://lirias.kuleuven.be/handle/123456789/545522